ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Takara Bio drives Japan's quest for a coronavirus vaccine

Pharmaceutical maker boasts twin strengths in testing and DNA technology

Takara Bio will produce a vaccine form the DNA of the coronavirus, an approach never used in humans before.   © Reuters

OSAKA -- As nations scramble to develop vaccines for the coronavirus, Takara Bio is at the forefront of Japan's efforts, tapping its four decades of gene-editing experience to help develop a DNA-based approach that has never been used in humans before.

The pharmaceutical maker is in a unique position during the pandemic: It is not only Asia's largest supplier of the reagents used in testing for the virus, but also is in the forefront of developing a DNA vaccine that could be put into mass production quickly to meet demand.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more